BiotechTube

SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Conditions

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Trial Timeline

Oct 1, 2021 → Oct 1, 2023

NCT ID
NCT04948788

About SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin

SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04948788. Target conditions include Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04948788Phase 2UNKNOWN

Competing Products

20 competing products in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
KPL-914Kiniksa PharmaceuticalsPhase 2
47
KPL-387Kiniksa PharmaceuticalsPhase 2
47
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
72
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
33
PLX3397Daiichi SankyoPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
Eribulin MesylateEisaiPre-clinical
23
Lenvatinib + EverolimusEisaiPhase 1/2
41
E7090EisaiPhase 2
52
LenvatinibEisaiPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85